U.S. Markets closed

Midatech Pharma plc (MTPH.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
27.25+1.75 (+6.86%)
At close: 4:17PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.50
Open25.88
Bid0.00 x 0
Ask0.00 x 0
Day's Range25.88 - 28.80
52 Week Range24.00 - 51.95
Volume1,594,703
Avg. Volume399,298
Market Cap17.271M
Beta (5Y Monthly)1.75
PE Ratio (TTM)N/A
EPS (TTM)-51.80
Earnings DateMay 17, 2021 - May 21, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est67.00
  • ACCESSWIRE

    Midatech Pharma PLC Announces Notice of Interim Results

    ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021.

  • ACCESSWIRE

    Midatech Pharma PLC Announces Appointment of Chief Scientific Officer

    Midatech Pharma PLC ('Midatech' or the 'Company') Midatech Strengthens Management Team with Appointment of Dr. Dmitry Zamoryakhin as Chief Scientific OfficerABINGDON, OXFORDSHIRE / ACCESSWIRE / July 12, 2021 / Midatech Pharma PLC (AIM:MTPH; Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the appointment of Dr.

  • Benzinga

    Midatech Pharma Secures £10M In Equity To Fund Product Development

    Midatech Pharma plc (NASDAQ: MTP) has raised £10 million from equity placing to fund its product development pipeline. Approximately 35 million new shares in the Company were issued at 28.5p each, a 12% discount on Monday's closing price. Considering available cash resources and the expected net proceeds, the Company expects sufficient cash resources to fund operations into Q1 of 2023. The proceeds will be used to develop its Q-Sphera technology following the success with the exemplar mAb disclo